Peptide compounds for suppressing inflammation
Provided herein are peptides that exhibit ApoE biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications.
1. A peptide selected from the group consisting of:
and pharmaceutically acceptable salts thereof.
2. A method of reducing inflammation in a subject in need thereof, the method comprising administering to the subject an effective amount of a peptide of claim 1 , or a pharmaceutically acceptable salt thereof.
3. The method of claim 2 , the method comprising administering the peptide by an injection, inhalation, transdermal, intravenous, intranasal, intracranial, and/or intrathecal route.
4. A method of claim 2 , wherein said peptide is a compound having the structure:
or a pharmaceutically acceptable salt thereof.
5. The method of claim 4 , the method comprising administering the peptide by an injection, inhalation, transdermal, intravenous, intranasal, intracranial, and/or intrathecal route.
6. A method of claim 2 , wherein said peptide is a compound having the structure:
or a pharmaceutically acceptable salt thereof.
7. The method of claim 6 , the method comprising administering the peptide by an injection, inhalation, transdermal, intravenous, intranasal, intracranial, and/or intrathecal route.
8. A method of treating a neurological condition in a subject in need thereof, the method comprising administering to the subject a composition comprising an effective amount of a peptide of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the neurological condition is traumatic CNS injury or stroke.
9. A method of claim 8 , wherein said peptide is a compound having the structure:
or a pharmaceutically acceptable salt thereof.
10. The method of claim 9 , the method comprising administering the peptide by an injection, inhalation, transdermal, intravenous, intranasal, intracranial, and/or intrathecal route.
11. A method of claim 8 , wherein said peptide is a compound having the structure:
or a pharmaceutically acceptable salt thereof.
12. The method of claim 11 , the method comprising administering the peptide by an injection, inhalation, transdermal, intravenous, intranasal, intracranial, and/or intrathecal route.
13. The method of claim 8 , the method comprising administering the peptide by an injection, inhalation, transdermal, intravenous, intranasal, intracranial, and/or intrathecal route.
14. A peptide of claim 1 , wherein said peptide is a compound having the structure:
or a pharmaceutically acceptable salt thereof.
15. A composition comprising the peptide of claim 14 and a pharmaceutically acceptable carrier, vehicle, diluent, or adjuvant.
16. A composition comprising the peptide of claim 1 and a pharmaceutically acceptable carrier, vehicle, diluent, or adjuvant.
17. A peptide of claim 1 , wherein said peptide is a compound having the structure:
or a pharmaceutically acceptable salt thereof.
18. A composition comprising the peptide of claim 17 and a pharmaceutically acceptable carrier, vehicle, diluent, or adjuvant.